[Federal Register Volume 74, Number 48 (Friday, March 13, 2009)]
[Notices]
[Page 10884]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-5486]


-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[Docket 8-2009]


Review of Sourcing Change, Foreign-Trade Subzone 7M, Amgen 
Manufacturing Limited (Biotechnology and Healthcare Products), Juncos, 
Puerto Rico

    Pursuant to the regulations of the Foreign-Trade Zones (FTZ) Board 
(the Board), a review has been initiated (under 15 CFR Sec. 
400.28(a)(3)(iii)(A)) of changes in sourcing related to certain 
packaging products at Foreign-Trade Subzone 7M, at the facility of 
Amgen Manufacturing Limited (Amgen), in Juncos, Puerto Rico.
    Subzone 7M was approved by the Board on December 11, 2008 (Board 
Order 1597, 73 FR 78290-78291, 12/22/08), for the manufacturing and 
distribution of biotechnology and healthcare products under FTZ 
procedures. On products shipped to the U.S. market, the company is able 
to choose the duty rate during customs entry procedures that applies to 
the finished products (duty-free) for the otherwise dutiable foreign 
components (duty-free to 2.7%). Components sourced from abroad include 
vials, syringes, stoppers, plunger rods, partitions and dispenser 
packs.
    Amgen has now notified the Board of additional sourcing of foreign 
packaging components. The imported components are PVC film (duty rate 
5.8%) and a plastic device to be used with a syringe in the self-
injection process (duty rate, 5.3%). The use of FTZ procedures for the 
additional components could exempt Amgen from customs duty payments on 
the foreign components used in export production. The company estimates 
that some 48 percent of the plant's shipments are exported. On its 
domestic sales, Amgen would be able to choose the duty rate during 
customs entry procedures that applies to the finished pharmaceutical 
products (duty-free) for the foreign inputs noted above. The finished 
pharmaceutical products remain unchanged and were included in the scope 
of manufacturing authority approved by the FTZ Board.
    In accordance with the Board's regulations, Elizabeth Whiteman is 
designated examiner to investigate the sourcing change, including its 
potential to cause ``significant adverse effects''' (15 CFR 
400.28(a)(3)(iii)(A)), and report to the Board.Public comment is 
invited from interested parties. Submissions (original and 3 copies) 
shall be addressed to the Board's Executive Secretary at the address 
below. The closing period for their receipt is April 13, 2009. Rebuttal 
comments in response to material submitted during the foregoing period 
may be submitted during the subsequent 15-day period to April 27, 2009.
    A copy of the sourcing change notification will be available for 
public inspection at the Office of the Executive Secretary, Foreign-
Trade Zones Board, Room 2111, U.S. Department of Commerce, 1401 
Constitution Avenue, NW, Washington, DC 20230-0002, and in the 
``Reading Room'' section of the Board's website, which is accessible 
via www.trade.gov/ftz.
    For further information, contact Elizabeth Whiteman at <a href="/cdn-cgi/l/email-protection#27624b4e5d464542534f78704f4e53424a4649674e53460943484409404851"><span class="__cf_email__" data-cfemail="17527b7e6d767572637f48407f7e63727a7679577e63763973787439707861">[email protected]</span></a> or (202) 482-0473.

    Dated: March 5, 2009.
Andrew McGilvray,
Executive Secretary.
[FR Doc. E9-5486 Filed 3-12-09; 8:45 am]
BILLING CODE 3510-DS-S


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>